Cagrilintide registration describes 64-week weekly injections in overweight or obesity with type 2 diabetes
A ClinicalTrials.gov registration for cagrilintide describes randomized assignment to once-weekly subcutaneous cagrilintide or matched placebo for 64 weeks in people with overweight or obesity and type 2 diabetes, with no results posted.
2026 · Trial registration · n=330 · Human · Published November 16, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the registration describes
This is a trial registration in human participants, not a published results report. The source text provided does not state how many participants are enrolled. According to the registration, the study "will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight," and it describes cagrilintide as a new investigational medicine that doctors may not yet prescribe.
The registration states that each participant will either get cagrilintide or placebo, that the assignment is decided by chance, and that participants are two times more likely to receive cagrilintide than placebo. It lists two arms: an experimental cagrilintide arm and a placebo comparator arm using placebo matched to cagrilintide.
What it reports so far
No outcome data appear in the provided text. The registration describes the planned treatment period and overall participation length: both arms receive weekly subcutaneous injections for 64 weeks, and for each participant the study is described as lasting about 1 year and 6 months.
The registration also notes, in general terms, that like all medicines the study medicine may have side effects. It does not list specific adverse events, efficacy estimates, or endpoint definitions in the text provided here.
Reported dosing
The registration states the route, frequency, and duration but not a dose amount. Participants in the cagrilintide arm are described as receiving cagrilintide subcutaneously once weekly for 64 weeks, administered with a pen-injector as an adjunct to lifestyle intervention counselling. Participants in the placebo arm receive placebo matched to cagrilintide on the same schedule. No milligram strength is given in the source text.
Limitations
This is a registration record only, so there are no reported results, no participant characteristics, and no safety data to evaluate. The provided text does not state the enrollment number, the primary endpoint, the geographic setting, or the funding and sponsor affiliations.
Because no dose amount is listed, the regimen cannot be fully characterized from this record. A randomized placebo comparator is described, with unequal allocation favouring cagrilintide two to one, but whether the study is blinded is not stated in the text provided.
Regulatory context
Cagrilintide, also referred to as AM833 or NNC0174-0833 and coformulated with semaglutide as CagriSema, is not an FDA-approved drug for any use. The registration itself describes it as a new investigational medicine that doctors may not yet prescribe.
Study-reported dosing
| Regimen as reported | Population | Route | Source |
|---|---|---|---|
| Cagrilintide subcutaneously once weekly for 64 weeks, administered with a pen-injector as an adjunct to lifestyle intervention counsellingThe source text states the route, frequency, and duration but no dose amount or units. | Participants assigned to the experimental cagrilintide arm, described as people with overweight or obesity and type 2 diabetes | Subcutaneous | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (2026) Trial registrationHumann=330 |
| Placebo matched to cagrilintide subcutaneously once weekly for 64 weeksPlacebo is described as matched to cagrilintide and given with a pen-injector. | Participants assigned to the placebo comparator arm | Subcutaneous | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (2026) Trial registrationHumann=330 |
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The registration describes random assignment to cagrilintide or placebo.
“Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance.”
Allocation is unequal, favouring the cagrilintide arm two to one.
“Participants are two times more likely to get cagrilintide than placebo.”
The cagrilintide arm is described as receiving weekly subcutaneous injections for 64 weeks.
“Participants will receive cagrilintide subcutaneously once weekly for 64 weeks.”
Treatment is given with a pen-injector alongside lifestyle intervention counselling.
“Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.”
Total participation is described as about 1 year and 6 months.
“For each participant, the study will last for about 1 year and 6 months.”
The registration describes cagrilintide as investigational and not yet prescribable.
“Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide.”
Common questions
Was there a control group?
Yes. The registration lists a placebo comparator arm receiving placebo matched to cagrilintide subcutaneously once weekly for 64 weeks.
Does the registration report any results?
No. The provided text describes the planned design, arms, and duration only; it contains no outcome or adverse event data.
What dose of cagrilintide is listed?
The source text does not state a dose amount. It states only that cagrilintide is given subcutaneously once weekly for 64 weeks with a pen-injector.
How long are participants involved?
The registration states that for each participant the study will last for about 1 year and 6 months, with 64 weeks of weekly injections.
Source
- 1.Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (2026)Trial registrationhumann=330NCT NCT07220759